Literature DB >> 9334620

Prostate specific antigen reverse transcriptase-polymerase chain reaction assay in preoperative staging of prostate cancer.

J M Ignatoff1, M G Oefelein, W Watkin, J S Chmiel, K L Kaul.   

Abstract

PURPOSE: Extracapsular extension of prostate cancer occurs in a significant number of men believed to have clinically localized disease. We report the ability of the reverse transcriptase-polymerase chain reaction (RT-PCR) assay to predict preoperatively the pathological stage of cases of clinically localized prostate cancer.
MATERIALS AND METHODS: Since October 1994, 82 consecutive men with clinically localized prostate cancer had a venous blood RT-PCR assessment before radical retropubic prostatectomy. The extracted ribonucleic acid was reverse transcribed, amplified and the amplicon identity confirmed by prostate specific antigen (PSA) directed probe hybridization. An additional 31 patients were enrolled to provide appropriate positive (T + Nx/1M2) and negative (human female and benign prostatic hyperplasia) controls. Histological examination of the entire prostatectomy specimen was performed.
RESULTS: Positive RT-PCR assay results correlated significantly with skeletal metastases and elevated levels of serum PSA but they did not significantly improve our ability to identify prospectively patients with extracapsular extension over traditional predictors (serum PSA, Gleason score).
CONCLUSIONS: The role of molecular techniques in prostate cancer evaluation and prognosis continues to emerge. However, in our study we demonstrate no significant advantage in preoperative staging of prostate cancer using RT-PCR assay with PSA primers.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9334620     DOI: 10.1016/s0022-5347(01)64150-8

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  7 in total

1.  Peripheral blood rt-PCR assays for detection and prognosis of prostate cancer.

Authors:  Shahrokh F Shariat; Kevin M Slawin
Journal:  Rev Urol       Date:  2003

2.  The relationship of palliative transurethral resection of the prostate with disease progression in patients with prostate cancer.

Authors:  Tracey L Krupski; George J Stukenborg; Kihyuck Moon; Dan Theodorescu
Journal:  BJU Int       Date:  2010-11       Impact factor: 5.588

3.  Preoperative nested reverse transcription-polymerase chain reaction for prostate specific membrane antigen predicts non-organ confined disease in radical prostatectomy specimens.

Authors:  John Varkarakis; Charalambos Deliveliotis; Diamandis Sideris; Nikolaos Trakas; Aris Giannopoulos
Journal:  Urol Res       Date:  2003-04-23

4.  Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with CellSearch assay and association with bone metastases and with survival.

Authors:  Pauliina Helo; Angel M Cronin; Daniel C Danila; Sven Wenske; Rita Gonzalez-Espinoza; Aseem Anand; Michael Koscuiszka; Riina-Minna Väänänen; Kim Pettersson; Felix K-H Chun; Thomas Steuber; Hartwig Huland; Bertrand D Guillonneau; James A Eastham; Peter T Scardino; Martin Fleisher; Howard I Scher; Hans Lilja
Journal:  Clin Chem       Date:  2009-02-20       Impact factor: 8.327

Review 5.  Genomic signatures associated with the development, progression, and outcome of prostate cancer.

Authors:  Prateek Mendiratta; Phillip G Febbo
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

6.  Clusterin as a possible predictor for biochemical recurrence of prostate cancer following radical prostatectomy with intermediate Gleason scores: a preliminary report.

Authors:  M R Pins; J E Fiadjoe; F Korley; M Wong; A W Rademaker; B Jovanovic; T K Yoo; J M Kozlowski; A Raji; X J Yang; C Lee
Journal:  Prostate Cancer Prostatic Dis       Date:  2004       Impact factor: 5.554

7.  MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas.

Authors:  H Uemura; Y Nakagawa; K Yoshida; S Saga; K Yoshikawa; Y Hirao; E Oosterwijk
Journal:  Br J Cancer       Date:  1999-10       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.